Cogent Biosciences ended Q2 2025 with a net loss of $73.5 million as it ramped up clinical and operational activities. The company highlighted strong cash reserves and progress in clinical trials, particularly the SUMMIT trial for bezuclastinib, which met all endpoints. A recent public offering further strengthened its financial position ahead of key milestones expected later in the year.

Cogent Biosciences reported a net loss of $72.0 million for the first quarter of 2025, an increase from $58.3 million in the same period last year. The company ended the quarter with $245.7 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into late 2026, including key clinical trial readouts.

Cogent Biosciences reported its Q4 and full year 2024 financial results, highlighting upcoming data readouts from bezuclastinib pivotal clinical trials and a strong cash balance sufficient to fund operations into late 2026.

Cogent Biosciences reported its Q3 2024 financial results, highlighting the completion of enrollment in the Phase 3 PEAK trial, acceleration of enrollment in the SUMMIT trial, and initiation of a Phase 1 trial for the FGFR2 inhibitor, CGT-4859. The company's cash position is strong at $346 million, expected to fund operations into late 2026.

Cogent Biosciences reported its Q2 2024 financial results, with key highlights including the ongoing progress of SUMMIT, PEAK, and APEX clinical trials, and a cash position of $390 million expected to fund operations into 2027. The company's net loss for the quarter was $59.0 million, with increased R&D expenses.

Cogent Biosciences reported first quarter results, highlighting progress in clinical trials for bezuclastinib and a strong cash position to fund operations into 2027. Enrollment in APEX and PEAK trials is expected to be completed by the end of the year, with SUMMIT enrollment in Q2 2025, and topline results from all three trials anticipated in 2025.

Cogent Biosciences reported its Q4 and full-year 2023 financial results, highlighting the ongoing clinical trials of bezuclastinib and a strong cash position to fund operations into 2027.

Cogent Biosciences reported meaningful progress in developing bezuclastinib, with clinical data presentations planned for upcoming meetings and a cash runway into 2026.

Cogent Biosciences reported a net loss of $44.1 million for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $350.9 million, expected to fund operations into 2026. They presented positive data from the lead-in portion of Phase 3 PEAK study and selected FGFR2 clinical candidate.

Cogent Biosciences reported a net loss of $38.6 million for the first quarter of 2023. The company ended the quarter with $220.3 million in cash, which is expected to fund operations into 2025. The company is progressing with its clinical trials for bezuclastinib and presented preclinical data from ErbB2 and FGFR2 research programs.

Cogent Biosciences reported a net loss of $39.6 million for the fourth quarter of 2022 and ended the year with $259.3 million in cash, sufficient to fund operations into 2025. The company highlighted progress with bezuclastinib in systemic mastocytosis and GIST and the initiation of the Phase 3 PEAK trial.

Cogent Biosciences reported a net loss of $35.1 million for the third quarter of 2022. As of September 30, 2022, cash, cash equivalents and marketable securities were $289.1 million, providing cash runway into 2025. The Phase 3 PEAK trial was initiated, and initial safety and pharmacokinetic data from the lead-in phase will be presented at CTOS 2022. An oral presentation at ASH 2022 will include an assessment of patient response from the Phase 2 APEX trial.

Cogent Biosciences reported positive initial clinical data from its APEX trial and secured additional financing to support its strategy into 2025. Cash and cash equivalents were $325.6 million as of June 30, 2022.

Cogent Biosciences reported a net loss of $30.6 million for the first quarter of 2022, with cash and cash equivalents totaling $191.0 million as of March 31, 2022. The company anticipates that its current cash reserves will fund operations into 2024.

Cogent Biosciences announced its Q4 and full year 2021 financial results, highlighting the active enrollment in APEX, SUMMIT, and PEAK clinical trials. The company ended the year with $219.7 million in cash and cash equivalents, expected to fund operations into 2024. An R&D Investor Event is planned for April 8, 2022.

Cogent Biosciences reported a net loss of $19.1 million for Q3 2021 and ended the quarter with $202.9 million in cash and cash equivalents. The company initiated the SUMMIT trial, a Phase 2 study of bezuclastinib in patients with nonadvanced systemic mastocytosis, and remains on track to initiate the PEAK trial for GIST patients in 2021.

Cogent Biosciences reported a net loss of $16.5 million for the second quarter of 2021, with cash and cash equivalents of $218.1 million as of June 30, 2021. The company initiated a Phase 2 clinical study for bezuclastinib in patients with Advanced Systemic Mastocytosis and expects to start the SUMMIT study for patients with Non-Advanced Systemic Mastocytosis in the second half of 2021.

Cogent Biosciences reported a net loss of $11.7 million for the first quarter of 2021, with R&D expenses at $8.2 million and G&A expenses at $4.6 million. The company ended the quarter with $230.7 million in cash and cash equivalents, expected to fund operations into 2024. Key highlights included IND clearance for a Phase 2 study of CGT9486 and the appointment of John Robinson as Chief Scientific Officer and Evan Kearns as Chief Legal Officer.

Cogent Biosciences reported a net loss of $11.3 million for the fourth quarter of 2020 and ended the quarter with $242.2 million in cash and cash equivalents.

Cogent Biosciences reported collaboration revenue of $0.3 million and a net loss of $50.0 million for the third quarter ended September 30, 2020. The company ended the quarter with $129.4 million in cash and cash equivalents.

Unum Therapeutics reported a collaboration revenue of $0.5 million, R&D expenses of $5.1 million, G&A expenses of $2.8 million, and a net loss of $7.4 million for the second quarter ended June 30, 2020. The company completed the acquisition of Kiq and is advancing clinical trials in Systemic Mastocytosis and Gastrointestinal Stromal Tumors ('GIST').

Unum Therapeutics reported a collaboration revenue of $7.0 million for the first quarter of 2020, compared to $3.1 million in the same period of 2019. The net loss attributable to common stockholders was $6.1 million, or $0.20 per share, compared to a net loss of $11.7 million, or $0.39 per share, for the same period in 2019. Cash and cash equivalents totaled $29.6 million as of March 31, 2020.

Unum Therapeutics reported collaboration revenues of $15.3 million for Q4 2019, a significant increase compared to $3.8 million for the same period in 2018, primarily due to the recognition of a portion of the upfront payment from Seattle Genetics, Inc. Net income attributable to common stockholders was $2.3 million, or $0.07 per share, for the fourth quarter of 2019, compared to a net loss of $8.6 million, or ($0.29) per share for the same period of 2018. As of December 31, 2019, Unum had cash and cash equivalents of $37.4 million.